argenx's Vyvgart Hytrulo Achieves Landmark Phase 3 Victory in Autoimmune Myositis
On August 17, 2026, argenx SE and its partner Zai Lab announced highly positive topline results from the pivotal global Phase 3 ALKIVIA trial (NCT05523167) evaluating subcutaneous Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with active autoimmune myositis. Autoimmune myositis is a rare, debilitating, and heterogeneous inflammatory muscle disorder with no approved targeted therapies in the United States.
Exceptional Efficacy in Combined Cohort and IMNM Subtype
The trial met its primary endpoint with high statistical significance. In the combined population of patients with immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM), Vyvgart Hytrulo-treated patients achieved a 15.4-point greater mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs 32.56; p=0.0011). Separation from placebo was observed as early as Week 4 and was sustained through the full year of treatment, even during a protocol-mandated corticosteroid taper.
In prespecified subtype analyses, Vyvgart Hytrulo delivered breakthrough results:
- IMNM Subtype: The trial met the primary endpoint in the IMNM cohort, showing a 14.8-point greater mean TIS improvement over placebo (45.05 vs 30.24; p=0.0048). This marks the first-ever Phase 3 trial to demonstrate a statistically significant and clinically meaningful reduction in disease activity for IMNM, a highly aggressive subtype characterized by severe muscle necrosis and profound weakness.
- Dermatomyositis (DM) Subtype: Patients in the DM cohort showed a comparable 14.5-point improvement (51.51 vs 36.96), which was highly clinically meaningful but did not reach statistical significance due to the smaller sample size (p=0.1093).
All six core set TIS measures—including muscle strength, everyday physical function, and extramuscular disease activity—favored efgartigimod across both subtypes.
Safety and Mechanism of Action
Efgartigimod is a first-in-class neonatal Fc receptor (FcRn) blocker that selectively reduces circulating pathogenic IgG autoantibodies while preserving other critical immune functions. The ALKIVIA results provide powerful clinical validation that pathogenic IgG autoantibodies are the primary drivers of disease activity in autoimmune myositis. Vyvgart Hytrulo was well tolerated, with a safety profile consistent with prior trials in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).
Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx, stated:
"These are the first Phase 3 results to show that precision targeting of FcRn with efgartigimod can deliver meaningful benefit in this disease. This confirms that pathogenic IgG autoantibodies are key drivers of autoimmune myositis."
Dr. Rohit Aggarwal, an ALKIVIA investigator and Professor of Medicine at the University of Pittsburgh, highlighted the clinical impact:
“For people living with myositis, the goal is straightforward: regain strength and function, and get off long-term steroids. Until now we have had limited targeted therapies to offer patients. That is what makes these results so compelling and groundbreaking.”
argenx and Zai Lab plan to present detailed results from the ALKIVIA study at an upcoming medical conference and intend to submit a Biologics License Application (BLA) to the FDA to seek regulatory approval.